Evaluation of Nefopam and Oxycodone for Pain Assessment in Patients with Chronic Pain

The primary objective of this study is to evaluate new test methods for the measurement of pain intensity in patients treated with nefopam and oxycodone. Establishing standardized measurement techniques is clinically significant for the accurate assessment of analgesic response in the management of chronic pain.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The participants fall within the age ranges corresponding to codes 3 and 4. Individuals with chronic pain are excluded from the study.

This Phase 3 clinical trial utilizes a research methodology to evaluate new testing methods for the measurement of chronic pain using two existing pharmacological agents, nefopam and oxycodone. The study design involves multiple stages, beginning with a screening visit to determine eligibility. Subsequent study visits are conducted to facilitate data collection and monitoring throughout the clinical process, concluding with an end-of-study visit. The total duration of the trial, including the recruitment period, is estimated to occur between August 2025 and February 2026. Participation may be discontinued prior to the completion of all scheduled visits if specific clinical criteria or termination conditions are met.

The assessment of efficacy in this phase 3 clinical trial focuses on the management of chronic pain. Specific parameters for evaluating therapeutic impact and clinical outcomes are utilized to determine the effectiveness of the intervention.